Skip to content
TheBrief.Health

Living with HER2 mutation

Stories from people navigating HER2 mutation — diagnosis, treatment, caregiving, and the ordinary days in between.

2 stories

A molecular pathology workstation displaying a lung tumor sequencing workflow without patient identifiers.

Oncology

Sevabertinib Makes HER2 Testing Actionable in NSCLC

FDA accelerated approval makes tumor HER2 kinase-domain mutation status treatment-defining for eligible adults with previously treated, advanced nonsquamous NSCLC.

Rayan Salih · September 23, 2026 · 7 min

Lung cancer tissue slide beside a molecular sequencing report highlighting an ERBB2 mutation

Oncology

Sevabertinib Approval Narrows HER2-Mutated NSCLC Use

FDA accelerated approval applies to previously treated, advanced non-squamous NSCLC with qualifying activating mutations in the HER2 tyrosine kinase domain—not every ERBB2 alteration.

Rayan Salih · 6 min read

Other conditions

One story a day

The story of the day, in your inbox

One health journey each morning — no advice, no alarm, just company for the road.